Indonesia University

ui.ac.id

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

447

Active

39

Phase 3

38

Total enrollment

59,099

Pipeline matrix

Showing 15 of 15 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Esomeprazole2
Propolis drops1
Vonoprazan 20 mg1
Simvastatin 40mg2
Tegoprazan1
Lansoprazole1
Mesenchymal Stromal/Stem Cells-Derived Exosomes (Exo-HWS + 1 vial Exo-HUVEC) Therapy1
Mesenchymal Stromal/Stem Cells-Derived Exosomes (Exo-HWS ) Therapy1
uc-msc secretome intra cavernous1
Oral Vitamin C1
Concentrated secretome Injection 3 mL1
Concentrated secretome Injection 3 mL with addition of TGF Beta 31
injection of local anesthesia solution1
Injection of normal saline1
Triple combination cream1

Next readouts

  • 2025-03
  • 2025-04-25
  • 2025-05
  • 2025-05-26
  • 2025-06-30
  • 2025-12-31
  • 2025-12-31
  • 2026-04-01
  • 2026-05-14
  • 2026-12-31

Top conditions

  • Obesity10
  • Surgery7
  • Sepsis7
  • Quality of Life6
  • Anesthesia6
  • Acne Vulgaris6
  • Oxidative Stress6
  • Diabetes Mellitus6

Frequently asked questions about Indonesia University

How many clinical trials does Indonesia University have on ClinicalTrials.gov?
Indonesia University is listed as the lead sponsor on 447 clinical trials in ClinicalTrials.gov, 39 of which are currently active (recruiting, enrolling, or ongoing).
How many of Indonesia University's trials are in Phase 3?
38 of Indonesia University's trials are in Phase 3, spread across 15 active drug programs.
What therapeutic areas does Indonesia University focus on?
Indonesia University's most-studied conditions on ClinicalTrials.gov are Obesity, Surgery, Sepsis, Quality of Life, Anesthesia.
When are Indonesia University's next clinical trial readouts?
Indonesia University has 10 upcoming primary-completion readouts tracked here; the soonest is “Effect of Vitamin C Supplementation in Corneal Endothelial Damage in Phacoemulsification of Patients with Hard Cataracts”, expected around 2025-03.